Goldman Sachs’s Unity Biotechnology UBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,066
| Closed | -$4K | – | 5361 |
|
|
2022
Q3 | $4K | Buy |
+1,066
| New | +$4K | ﹤0.01% | 5342 |
|
|
2022
Q2 | – | Sell |
-2,320
| Closed | -$26K | – | 5860 |
|
|
2022
Q1 | $26K | Sell |
2,320
-6,696
| -74% | -$75K | ﹤0.01% | 5577 |
|
|
2021
Q4 | $132K | Buy |
9,016
+4,848
| +116% | +$71K | ﹤0.01% | 5139 |
|
|
2021
Q3 | $125K | Sell |
4,168
-3,033
| -42% | -$91K | ﹤0.01% | 5015 |
|
|
2021
Q2 | $334K | Buy |
7,201
+247
| +4% | +$11.5K | ﹤0.01% | 4645 |
|
|
2021
Q1 | $418K | Sell |
6,954
-6,000
| -46% | -$361K | ﹤0.01% | 4474 |
|
|
2020
Q4 | $679K | Buy |
12,954
+7,096
| +121% | +$372K | ﹤0.01% | 3669 |
|
|
2020
Q3 | $203K | Sell |
5,858
-375
| -6% | -$13K | ﹤0.01% | 4056 |
|
|
2020
Q2 | $541K | Sell |
6,233
-290
| -4% | -$25.2K | ﹤0.01% | 3565 |
|
|
2020
Q1 | $379K | Sell |
6,523
-2,614
| -29% | -$152K | ﹤0.01% | 3634 |
|
|
2019
Q4 | $659K | Buy |
9,137
+1,554
| +20% | +$112K | ﹤0.01% | 3518 |
|
|
2019
Q3 | $463K | Sell |
7,583
-25,012
| -77% | -$1.53M | ﹤0.01% | 3626 |
|
|
2019
Q2 | $3.1M | Sell |
32,595
-1,415
| -4% | -$134K | ﹤0.01% | 2573 |
|
|
2019
Q1 | $2.76M | Sell |
34,010
-17,298
| -34% | -$1.4M | ﹤0.01% | 2756 |
|
|
2018
Q4 | $8.34M | Buy |
51,308
+1,641
| +3% | +$267K | ﹤0.01% | 2019 |
|
|
2018
Q3 | $8.09M | Sell |
49,667
-3,902
| -7% | -$636K | ﹤0.01% | 2166 |
|
|
2018
Q2 | $8.07M | Buy |
+53,569
| New | +$8.07M | ﹤0.01% | 2121 |
|